Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 2,727 |
|
|||||
| News | - |
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Revelation Biosciences Inc | REVBW | NASDAQ | Equity Warrant |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.0004 | 3.33% | 0.0124 | 15:37:18 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.0102 | 0.0101 | 0.0124 | 0.0124 | 0.012 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume |
|---|---|---|---|---|
| 11 | 2,727 | 0.0110999 | 30 | - |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:00:00 | 32 | 0.0124 | USD |
Revelation Biosciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 75.56k | 6.30M | - | 0 | -120k | -0.02 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News Revelation Biosciences
| Date | Time | Source | Heading |
|---|---|---|---|
| 11/08/2024 | 15:25 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/08/2024 | 15:00 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 10/21/2024 | 15:19 | Edgar (US Regulatory) | Form 8-K - Current report |
| 9/27/2024 | 15:09 | Edgar (US Regulatory) | Form 8-K - Current report |
| 9/23/2024 | 15:57 | Edgar (US Regulatory) | Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]:.. |
| 9/23/2024 | 15:55 | Edgar (US Regulatory) | Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]:.. |
| 9/23/2024 | 15:53 | Edgar (US Regulatory) | Form 10-K/A - Annual report [Section 13 and 15(d), not S-K.. |
| 9/13/2024 | 15:01 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 9/12/2024 | 23:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness |
| 8/09/2024 | 15:24 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/09/2024 | 15:01 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 6/18/2024 | 16:08 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
REVBW Historical
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. |
